INFLUX
Influx Healthtech financials
- Market cap
- ₹627 Cr
- Sector
- Healthcare
- Calls analysed
- 2
INFLUX Q4 FY26
What went well
- Revenue from operations stood at INR80.1 crores in H2 FY26, registering 41% year-on-year growth, bringing full year FY26 revenue to INR146 crores.
- PAT for H2 FY26 was INR10.5 crores, up 38% year-on-year, with full year PAT at INR20.5 crores, and full year PAT margin expanding by 129 bps points to 14%.
- Full year EBITDA margin expanded by 72 bps to 20.3%, with EBITDA at INR29.9 crores for FY26.
What to watch
- Gross margins declined from 44% in H1 to 39% in H2 FY26, attributed to product mix and a lag in passing on raw material price increases.
- Employee cost increased by 31% in H2 FY26 as compared to H1 FY26, and 34% for the full year to INR11.8 crores, due to workforce addition for new units and annual salary increments.
What Influx Healthtech Limited does
Influx Healthtech is a contract development and manufacturing organisation (CDMO) that develops and manufactures dietary/nutritional supplements, cosmetics, ayurvedic/herbal formulations, veterinary feed supplements and homecare products on behalf of client brands. It runs an end-to-end model spanning formulation development, manufacturing and regulatory support, allowing clients (multinationals, D2C brands and niche healthcare providers) to focus on their own product discovery and commercialisation. Manufacturing is carried out across facilities in Palghar, Maharashtra, and the company also exports its products, having secured regulatory clearances in additional international markets such as Tanzania.
Segments
- Nutraceuticals
- Cosmetics
- Ayurvedic/Herbal
- Veterinary feed & pet care
- Homecare
- Manufacturing units
- 4 (Palghar, Maharashtra; 1 of the 4 facilities is rented)
- Product range
- 3,428
- Client base
- 718 clients
- Client retention rate
- 98%
- Export countries
- 36
- Capacity utilization
- 70% (blended, FY26)
Guidance record · Q4 FY26
what the last two calls moved 13 tracked 1 delivered 2 missed 10 open- Regulatory Approvals delivered said Q2 FY26 Promised: Tanzania audit on Dec 11 Q4 FY26: Management confirmed in the detailed narrative that 'regulatory approvals secured in Tanzania and Nigeria', successfully completing this objective.
- Revenue missed said Q2 FY26 Promised: INR 150+ crores in FY26 Q4 FY26: Company reported full-year FY26 revenue of INR 146 crores, slightly missing the guided target of INR 150+ crores.
- Revenue at risk said Q2 FY26 Promised: Double the business by FY27 Q4 FY26: FY26 revenue closed at INR 146 Cr. Management's FY27 growth guidance of 25-30% (to ~INR 183-190 Cr) is not on a trajectory to double the FY25 base (~INR 105 Cr) by FY27.
All 13 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
| Line item | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|
| Revenue | 48 | 57 | 67 | 80 |
| EBITDA | 9 | 11 | 15 | 15 |
| Net profit | 6 | 8 | 10 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +40.0% 1Y
1Y: ₹193.55 on 10 Sept 2025 → ₹270.95. High ₹312.35 (6 Jul 2026), low ₹169 (1 Oct 2025).
How the price took the results
close before → close after
- Q4 FY26
- +7.1%
- 22 May
- Q2 FY26
- +5.0%
- 12 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹23 Cr | ₹23 Cr |
| Reserves | ₹0 Cr | ₹4 Cr | ₹12 Cr | ₹23 Cr | ₹67 Cr | ₹78 Cr |
| Borrowings | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other liabilities | ₹0 Cr | ₹12 Cr | ₹16 Cr | ₹18 Cr | ₹23 Cr | ₹23 Cr |
| Total liabilities | ₹0 Cr | ₹18 Cr | ₹28 Cr | ₹41 Cr | ₹114 Cr | ₹124 Cr |
| Fixed assets | ₹0 Cr | ₹3 Cr | ₹6 Cr | ₹14 Cr | ₹24 Cr | ₹28 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹3 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹34 Cr | ₹2 Cr |
| Other assets | ₹0 Cr | ₹15 Cr | ₹22 Cr | ₹27 Cr | ₹55 Cr | ₹90 Cr |
| Total assets | ₹0 Cr | ₹18 Cr | ₹28 Cr | ₹41 Cr | ₹114 Cr | ₹124 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Jun 2025, the public added +8.04 pp while DIIs trimmed −4.81 pp. The shareholder count shrank 44% to 1,335.
- Promoters
- 73.5%
- FIIs
- 0.2%
- DIIs
- 5.7%
- Public
- 20.7%
Since Jun 2025
- Public +8.04 pp
- DIIs −4.81 pp
- FIIs −3.22 pp
How it drifted, 3 quarters
Over this window the public went from 12.6% to 20.7% — +8.0 pp.
Ownership split by quarter, oldest first. Jun '25: Promoters 73.5%, FIIs 3.4%, DIIs 10.5%, Public 12.6%.Sep '25: Promoters 73.5%, FIIs 1.8%, DIIs 6.8%, Public 17.8%.Mar '26: Promoters 73.5%, FIIs 0.2%, DIIs 5.7%, Public 20.7%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Kulbhushan Parashar newly disclosed 1.87% held
- Key Managerial Personnel newly disclosed 0.00% held
The same filing shows 2 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Influx Healthtech Limited above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Munir Abdul Ganee Chandniwala | 69.73% | unchanged |
| Shirin Munir Ahmed Chandniwala | 3.80% | unchanged |
| Kulbhushan Parashar | 1.87% | newly disclosed |
| Ccv Emerging Opportunities Fund-I AIF | 1.85% | −0.46 pp |
| Aarth AIF Growth Fund AIF | 1.40% | −0.38 pp |
| Finavenue Capital Trust - Finavenue Growth Fund AIF | 1.35% | unchanged |
| Haradwala Sufaiyabibi S | 0.00% | unchanged |
| Mohmadjamal Abdulnabi Sabugar | 0.00% | unchanged |
| Taherabibi A Maja | 0.00% | unchanged |
| Ahmedhusan Hajiaabdul Rasul Chandniwala | 0.00% | unchanged |
| Shabanabegum Z Doi | 0.00% | unchanged |
| Abdul Ganee Abdul Rasul Chandniwala | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 10.1% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
All earnings calls (2)
Read the Q4 FY26 call →Learn to analyse Influx Healthtech Limited
Guides on how to read this kind of business and the numbers that matter.